From Financial Modeling Prep: 2025-03-19 07:00:06

Geron Corporation has a ROIC of -34.35%, not meeting its cost of capital due to heavy investments in cancer therapeutics research. Stem, Inc. shows a slightly better capital efficiency with a ROIC of -0.09%, while Agenus Inc. faces significant capital utilization inefficiencies with a ROIC of -813.12%. Exelixis, Inc. shines with a positive ROIC of 18.19%, indicating efficient capital utilization and growth potential.



Read more at Financial Modeling Prep:: Geron Corporation’s Financial Performance in the B…